SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2) ...
GLP-1 RA use was associated with significantly lower epilepsy risk, with protective associations seen at 1, 3, and 5 years. (HealthDay News) — For adults with type 2 diabetes mellitus (T2DM), glucagon ...
The trial involved 81 children between the ages of 2 and 18 that suffered up to 18 seizures a month resulting from Dravet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results